Pfizer racks up an FDA approval for eczema blockbuster hopeful crisaborole
Pfizer will now get a chance to see if the eczema drug crisaborole is really worth up to or beyond $2 billion in annual sales …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
